SOURCE: GelStat Corporation

August 29, 2007 08:00 ET

Wall Street Resources Releases a Comprehensive Report on GelStat Corporation Reflecting All of the Company's Recent Developments

ST. PAUL, MN--(Marketwire - August 29, 2007) - GelStat Corporation (PINKSHEETS: GSAC), a consumer healthcare company primarily focused on the development and marketing of over-the-counter (OTC) products for the safe and effective treatment of pain and inflammation, today announces the release of a comprehensive report on the Company written by Gerald N. Kieft of Wall Street Resources, Inc.

The free report is available at: www.wallstreetresources.net/gelstat.asp The 31-page report includes detailed information on the Company's business model, products, industry, valuation, management and risks.

Jim LaFlamme, Chief Executive Officer of GelStat, commented, "There have been a number of meaningful changes to GelStat over the last eight months and this report gives current and prospective investors a broad overview of these changes, as well as the future direction of the Company."

Mr. Kieft stated, "Our firm has followed GelStat since November of 2003 and has received countless endorsements on the effectiveness of the Company's products over that time. It was that feedback that held our interest and maintained our firm belief that the Company would be successful. After witnessing the transformation of the Company since U.S. Marketing took the helm in January of 2007, we are more confident than ever before."

About GelStat Corporation

GelStat Corporation is dedicated to providing safe and effective over-the-counter (OTC) treatments for pain and inflammation. GelStat's first product, GelStat Migraine, is sold nationwide through retail chain stores, independent retailers and pharmacies, and direct to consumer channels. GelStat Migraine is a sublingually (under the tongue) administered OTC medication for acute relief from the pain and associated symptoms of migraine. Over 90 percent of the 30 million Americans with migraine use OTC headache remedies, generally aspirin or other non-steroidal anti-inflammatory drugs. Americans spend $2.6 billion each year on 600 million units of such products, although they are believed to be effective for only about 25 percent of those with moderate to severe migraine.

The Company also has a suite of additional, effective healthcare products that address large consumer markets. GelStat™ Arthritis is the second available product to utilize GelStat's patent-pending formulation and is provided as a daily use, sublingual dissolving tablet. The Center for Disease Control estimates that, in its many forms, arthritis affects up to 70 million Americans. The Company has also developed "GelStat™ Sinus" and "GelStat™ Sleep," and believes that each of these products performs well and is effective for its intended use. The National Institute of Allergy and Infectious Disease estimates that 37 million Americans are affected by sinusitis every year, with at least 20 million more suffering from allergies. Approximately 70 million Americans are reported to be "problem sleepers."

For more information, visit www.gelstat.com

About Wall Street Resources

Wall Street Resources, Inc. and its affiliated site http://www.wallstreetresources.net is a leading source for information on micro-to-small capital publicly traded companies and its principal's have over 25 years of experience providing analysis on these companies. Wall Street Resources (WSR) acts as a conduit between micro-to-small capital company investors and emerging growth companies through its proprietary financial publications including daily and monthly newsletters, as well as comprehensive 20-50 page featured company reports. To sign up to receive WSR's financial publications go to: http://www.wallstreetresources.net/signup_basic_indiv.asp WSR also provides business consulting services to help corporate executives by writing analytical reports, building financial models, and developing business plans.

Disclaimer -- We, our affiliates, and any officer, director or stockholder or any member of their families may have a position in and may from time to time purchase or sell any securities discussed in our financial publications. There may be instances when fundamental, technical, and quantitative opinions may not be in concert. Our associates may from time to time perform investment banking or other services for, or solicit investment banking or other business from, any company mentioned in our reports. WSR is a consultant to the Company and has received $10,000 in cash and 495,000 shares of 144 restricted stock for due diligence fees and consulting services from December of 2003 to November of 2007.

Safe Harbor Statement Under the Private Securities Litigation Act of 1995

With the exception of historical information, the matters discussed in this press release are forward-looking statements that involve a number of risks and uncertainties. The actual future results of GelStat could differ significantly from those statements. Factors that could cause actual results to differ materially include risks and uncertainties such as the inability to finance the company's operations or expansion, inability to hire and retain qualified personnel, changes in the general economic climate, including rising interest rate and unanticipated events such as terrorist activities. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "expect," "plan," "anticipate," "believe," "estimate," "predict," "potential," or "continue," the negative of such terms, or other comparable terminology. These statements are only predictions. Although we believe that the expectations reflected in the forward-looking statements are reasonable, such statements should not be regarded as a representation by the Company, or any other person, that such forward-looking statements will be achieved. We undertake no duty to update any of the forward-looking statements, whether as a result of new information, future events or otherwise. In light of the foregoing, readers are cautioned not to place undue reliance on such forward-looking statements. For further risk factors, please review our SEC filings.

Contact Information